Discover useful biomarkers to predict the risk of brain metastases in patients with breast cancer

4 08 2011

A study coordinated by the researcher in the Group of key biological phenotype invasive and metastatic at the Instituto de Bellvitge biomedical research (IDIBELL), Sierra Angels, It shows that the overexpression of certain proteins in the primary tumor predicts the risk of developing metastasis in patients with breast cancer. The research is part of the program of projects of development of the University of Barcelona-Santander managed by the Area of valuation and licensing of the Bosch Foundation i Gimpera. The results are published in the August issue of the magazine The American Journal of Pathology.

So far not known predictors of brain metastasis, complication affecting to a 30% of patients with breast cancer who develop metastases. These biomarkers allow the prediction of the risk in patients with ErbB2-positive tumors (the ErbB2 oncogene amplification) as triple negative tumors (estrogen receptor, negative, progesterone and ErbB2 receptor). Its use would be particularly beneficial for cataloging such patients, two subgroups that are more likely to develop brain metastases, and in which the involvement of the central nervous system drastically delimits the survival of the patients.

Biomarkers of metastasis

The use of markers of brain metastasis will contribute to monitoring and personalised treatment of patients. On the one hand, know the presence of the biomarker help plan aimed at early diagnostic scans; and, On the other hand, the overexpression of these proteins may indicate the use of therapies, either to prevent or to treat the brain metastasis, other than those that apply at this time, some of them in the process of clinical development.

The work has been the result of applying systems biology to the systematization of information Transcriptomics and proteomics, to generate protein-protein interaction networks that define the characteristic of breast cancer cells phenotype with ability to metastasise in brain.

The study conducted by the Angels Sierra researcher of the laboratory of pathogenesis of the Metastasis of the biological key of the invasive and metastatic IDIBELL phenotype group has been possible thanks to the close collaboration of clinicians and biomedical research in three countries. Together with researchers from IDIBELL, have participated in clinical trials of the functional breast unit and unit of Biostatistics and Bioinformatics of l'Institut Català of Oncology of the Hospital Duran i Reynals; Service of neurosurgery, Anatomical pathology department and Institute of neuropathology of the Bellvitge University Hospital; Structural bioinformatics at the Universitat Pompeu Fabra group; Network of Bank of tumours of Catalunya and Hospital clinical/IDIBAPS pathological anatomy Department. They have also participated French scientists of the Institute Curie of the Centre René Huguenin de St Cloud, and of the Curie Institute in Paris, and the Department of pathology of the Academic Medical Center in Amsterdam.

The work has been funded by the European Union, the Ministry of science and education, the Instituto de Salud Carlos III and the Xarxa Bancs Tumors of Catalunya.

The validation of these results in a large number of clinical specimens (around 300) you are performing with funding from the University of Barcelona-Santander recovery projects program, managed by the Fundació Bosch i Gimpera (Center for knowledge transfer, Technology and innovation at the University of Barcelona), cuyos resultados se esperan obtener a principios de septiembre.

The article reference

Sanz-Pamplona R.*, Aragües R., Driouch K., Martín B.*, Oliva B., Gil M., Boluda S.*, Fernández P.*, Martínez A.*, Moreno V., Acebes J.*, Lidereau R., Reyal F., Van de Vijver M. And Sierra A.*. Expression of Endoplasmic Reticulum StressProteins Is a Candidate Marker of Brain Metastasis in both ErbB-2_ and ErbB-2_ Primary Breast Tumors. The American Journal of Pathology, Vol. 179, No. 2, August 2011




Leave a comment

You can use these tags : <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>